Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
11.48
+0.17 (1.52%)
Nov 21, 2024, 2:40 PM EST - Market open
Evolent Health Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Evolent Health stock have an average target of 28.9, with a low estimate of 16 and a high estimate of 45. The average target predicts an increase of 151.70% from the current stock price of 11.48.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Evolent Health stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 3 | 3 |
| Buy | 4 | 5 | 5 | 5 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $34 → $28 | Buy | Maintains | $34 → $28 | +143.86% | Nov 18, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $33 → $21 | Strong Buy | Maintains | $33 → $21 | +82.89% | Nov 13, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $20 | Buy | Reiterates | $20 | +74.19% | Nov 12, 2024 |
| Barclays | Barclays | Buy Maintains $39 → $19 | Buy | Maintains | $39 → $19 | +65.48% | Nov 11, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $45 → $34 | Buy | Maintains | $45 → $34 | +196.12% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
2.60B
from 1.96B
Increased by 32.39%
Revenue Next Year
2.98B
from 2.60B
Increased by 14.42%
EPS This Year
1.36
from -1.28
EPS Next Year
1.66
from 1.36
Increased by 22.30%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.7B | 3.2B | 3.9B | ||
| Avg | 2.6B | 3.0B | 3.4B | ||
| Low | 2.5B | 2.7B | 3.0B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 38.8% | 24.2% | 30.2% | ||
| Avg | 32.4% | 14.4% | 15.7% | ||
| Low | 27.2% | 4.9% | -0.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.58 | 2.34 | 3.03 | ||
| Avg | 1.36 | 1.66 | 2.15 | ||
| Low | 0.97 | 0.85 | 1.39 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 72.1% | 82.4% | ||
| Avg | - | 22.3% | 29.4% | ||
| Low | - | -37.3% | -16.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.